PatrÃ-cio Soares da Silva

List of Publications by Year
in descending order

388 papers	11,484 citations	30070 54 h-index	53230 85 g-index
392 all docs	392 docs citations	392 times ranked	8254 citing authors

#	Article	IF	Citations
1	Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10â€2474: A Doubleâ€Blind, Randomized, Placeboâ€Controlled Study in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2022, 111, 391-403.	4.7	11
2	In vitro and in vivo antiâ€epileptic efficacy of eslicarbazepine acetate in a mouse model of KCNQ2â€related selfâ€limited epilepsy. British Journal of Pharmacology, 2022, 179, 84-102.	5.4	6
3	Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinsonâ€™s Disease Patients with Motor Fluctuations. European Neurology, 2022, , 1-9.	1.4	1
4	Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease. Neurodegenerative Disease Management, 2022, 12, 77-91.	2.2	4
5	Opicapone versus placebo in the treatment of Parkinsonâ€™s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone) Tj ETQq1 1 0.784314 rgBT /Ov		
6	Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping. Pharmacology Research and Perspectives, 2022, 10, e00891.	2.4	4
7	Absorption, metabolism and excretion of opicapone in human healthy volunteers. British Journal of Clinical Pharmacology, 2022, , .	2.4	4
8	Opicapone as an Add-on to Levodopa in Patients with Parkinsonâ€™s Disease Without Motor Fluctuations: Rationale and Design of the PhaseÂIII, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial. Neurology and Therapy, 2022, 11, 1409-1425.	3.2	5
9	Salt-inducible kinases: new players in pulmonary arterial hypertension?. Trends in Pharmacological Sciences, 2022, 43, 806-819.	8.7	6
10	Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (â‰¥60 years) and younger (18â€“59 years) adults. Epilepsy Research, 2021, 169, 106478.	1.6	3
11	Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys. European Journal of Pharmacology, 2021, 892, 173742.	3.5	4
12	Non-clinical toxicology evaluation of BIA 10-2474. Critical Reviews in Toxicology, 2021, 51, 65-75.	3.9	3
13	Complex effects of eslicarbazepine on inhibitory micro networks in chronic experimental epilepsy. Epilepsia, 2021, 62, 542-556.	5.1	4
14	Antagonistic modulation of SIK1 and SIK2 isoforms in high blood pressure and cardiac hypertrophy triggered by high-salt intake. Clinical and Experimental Hypertension, 2021, 43, 1-8.	1.3	5
15	The role of salt-inducible kinases on the modulation of renal and intestinal Na+,K+-ATPase activity during short- and long-term high-salt intake. European Journal of Pharmacology, 2021, 904, 174153.	3.5	2
16	Safety of Eslicarbazepine Acetate in Elderly Versus Non-Elderly Patients with Focal Seizures: From Pooled Data of Clinical Studies to 8 Years of Post-Marketing Experience. Drug Safety, 2021, 44, 1099-1107.	3.2	4
17	Redefining the strategy for the use of COMT inhibitors in Parkinsonâ€™s disease: the role of opicapone. Expert Review of Neurotherapeutics, 2021, 21, 1019-1033.	2.8	17
18	The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II. Frontiers in Neurology, 2021, 12, 754016.	2.4	7

#	Article	IF	Citations
19	Effects of nepicastat upon dopamine-Î²-hydroxylase activity and dopamine and norepinephrine levels in the rat left ventricle, kidney, and adrenal gland. Clinical and Experimental Hypertension, 2020, 42, 118-125.	1.3	11
20	Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate. Acta Neurologica Scandinavica, 2020, 141, 397-404.	2.1	9
21	Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10â€2474. British Journal of Pharmacology, 2020, 177, 2123-2142.	5.4	11
22	Longâ€term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An openâ€label extension study. Epilepsia, 2020, 61, 2129-2141.	5.1	7
23	Liver says no: the ongoing search for safe catechol O-methyltransferase inhibitors to replace tolcapone. Drug Discovery Today, 2020, 25, 1846-1854.	6.4	16
24	Effectiveness and safety of opicapone in Parkinsonâ€™s disease patients with motor fluctuations: the OPTIPARK open-label study. Translational Neurodegeneration, 2020, 9, 9.	8.0	35
25	Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial. Epilepsy and Behavior, 2020, 105, 106962.	1.7	16
26	Regulatory safety pharmacology evaluation of BIA 10-2474. Journal of Pharmacological and Toxicological Methods, 2020, 102, 106677.	0.7	5
27	In vitro Species Different Metabolism and CYP Phenotyping of Zamicastast. FASEB Journal, 2020, 34, 1-1.	0.5	1
28	Zamicastat is a noncompetitive Dopamineâ€Î²â€hydroxylase inhibitor that modulates sympathetic nervous system activity. FASEB Journal, 2020, 34, 1-1.	0.5	0
29	Bioelectrical impedance analysis of body composition for the anesthetic induction dose of propofol in older patients. BMC Anesthesiology, 2019, 19, 180.	1.8	1
30	Cardiometabolic and Inflammatory Benefits of Sympathetic Down-Regulation with Zamicastat in Aged Spontaneously Hypertensive Rats. ACS Pharmacology and Translational Science, 2019, 2, 353-360.	4.9	5
31	Safety Profile of Opicapone in the Management of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2019, 9, 733-740.	2.8	25
32	Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors. European Journal of Pharmacology, 2019, 847, 53-60.	3.5	9
33	Contemporary Options for the Management of Motor Complications in Parkinsonâ€™s Disease: Updated Clinical Review. Drugs, 2019, 79, 593-608.	10.9	30
34	Acute salt loading induces sympathetic nervous system overdrive in mice lacking salt-inducible kinase 1 (SIK1). Hypertension Research, 2019, 42, 1114-1124.	2.7	10
35	Repurposing nitrocatechols: 5-Nitro-Î±-cyanocarboxamide derivatives of caffeic acid and caffeic acid phenethyl ester effectively inhibit aggregation of tau-derived hexapeptide AcPHF6. European Journal of Medicinal Chemistry, 2019, 167, 146-152.	5.5	20
36	Population Pharmacokineticâ€Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS). Journal of Clinical Pharmacology, 2019, 60, 617.	2.0	10

#	Article	IF	Citations
37	Effects of zamicastat treatment in a genetic model of salt-sensitive hypertension and heart failure. European Journal of Pharmacology, 2019, 842, 125-132.	3.5	6
38	Antihypertensive effect of etamicastat in dopamine D2 receptor-deficient mice. Hypertension Research, 2018, 41, 489-498.	2.7	9
39	Response: Comparing the dosages of lacosamide, eslicarbazepine acetate, and controlledâ€•release carbamazepine in noninferiority epilepsy monotherapy trials: How much â€œfairâ€•is â€œfairâ€• Epilepsia, 2018, 59, 900-901.	5.1	0
40	In vitro assessment of the interactions of dopamine Î²-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein. European Journal of Pharmaceutical Sciences, 2018, 117, 35-40.	4.0	9
41	Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs. Epilepsy Research, 2018, 141, 83-89.	1.6	9
42	Efficacy and safety of eslicarbazepine acetate versus controlledâ€•release carbamazepine monotherapy in newly diagnosed epilepsy: A phase <scp>III</scp> doubleâ€•blind, randomized, parallelâ€•group, multicenter study. Epilepsia, 2018, 59, 479-491.	5.1	69
43	Eslicarbazepine acetate exposure in pregnant women with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2018, 58, 72-74.	2.0	12
44	Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology, 2018, 90, e1849-e1857.	1.1	40
45	Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials. Epilepsy Research, 2018, 139, 1-8.	1.6	10
46	Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Agedâ€‰â‰¥â€‰65ÂYears with Focal Seizures. Drugs and Aging, 2018, 35, 1109-1117.	2.7	13
47	Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration. Neuropharmacology, 2018, 143, 282-288.	4.1	4
48	Polyamine Modulation of Anticonvulsant Drug Response: A Potential Mechanism Contributing to Pharmacoresistance in Chronic Epilepsy. Journal of Neuroscience, 2018, 38, 5596-5605.	3.6	11
49	Effects of eslicarbazepine on slow inactivation processes of sodium channels in dentate gyrus granule cells. Epilepsia, 2018, 59, 1492-1506.	5.1	13
50	Discovery of a Potent, Longâ€•Acting, and CNSâ€•Active Inhibitor (BIA 10â€•2474) of Fatty Acid Amide Hydrolase. ChemMedChem, 2018, 13, 2177-2188.	3.2	21
51	DISTRIBUTION, METABOLISM AND ELIMINATION OF OPICAPONE IN THE RAT AND NON-HUMAN PRIMATE. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-28.	0.0	1
52	IN VITRO ASSEMENT OF POTENTIAL DRUG INTERACTION OF OPICAPONE, A NOVEL COMT INHIBITOR. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-15.	0.0	0
53	DISTRIBUTION, METABOLISM AND ELIMINATION OF BIA 10â€•2474 IN THE RAT. FASEB Journal, 2018, 32, 833.3.	0.5	1
54	EVALUATION OF THE POTENCY AND SELECTIVITY OF THE NOVEL FAAH INHIBITOR BIA 10â€•2474 IN COMPARISON WITH PFâ€•04457845 AND JNJâ€•42165279. FASEB Journal, 2018, 32, 692.14.	0.5	2

#	Article	IF	Citations
55	The effect of PRR ligands on the membrane potential of intestinal epithelial cells. Pharmacological Reports, 2017, 69, 978-984.	3.3	9
56	Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat. Toxicology and Applied Pharmacology, 2017, 323, 9-15.	2.8	5
57	Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations. JAMA Neurology, 2017, 74, 197.	9.0	146
58	Pooled efficacy and safety of eslicarbazepine acetate as addâ€on treatment in patients with focalâ€onset seizures: Data from four doubleâ€blind placeboâ€controlled pivotal phase <scp>III</scp> clinical studies. CNS Neuroscience and Therapeutics, 2017, 23, 961-972.	3.9	25
59	Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors. Drug Metabolism and Disposition, 2017, 45, 1282-1291.	3.3	19
60	A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat. Neuropharmacology, 2017, 125, 146-155.	4.1	6
61	Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience. Drug Safety, 2017, 40, 1231-1240.	3.2	18
62	Effect of opicapone multipleâ€dose regimens on levodopa pharmacokinetics. British Journal of Clinical Pharmacology, 2017, 83, 540-553.	2.4	14
63	Amine neurotransmitters, inflammation and epithelial sodium transport. Experimental Physiology, 2016, 101, 459-464.	2.0	7
64	Development of a liquid chromatography assay for the determination of opicapone and BIA 9â€“1079 in rat matrices. Biomedical Chromatography, 2016, 30, 312-322.	1.7	6
65	Sustained high blood pressure reduction with etamicastat, a peripheral selective dopamine Î²-hydroxylase inhibitor. Journal of the American Society of Hypertension, 2016, 10, 207-216.	2.3	9
66	Role of epithelial ion transports in inflammatory bowel disease. American Journal of Physiology - Renal Physiology, 2016, 310, G460-G476.	3.4	33
67	Synthesis and structureâ€“activity relationships of ionizable 1,3,4-oxadiazol-2(3H)-ones as peripherally selective FAAH inhibitors with improved aqueous solubility. Pure and Applied Chemistry, 2016, 88, 341-347.	1.9	3
68	Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects. Clinical Pharmacology in Drug Development, 2016, 5, 150-161.	1.6	22
69	Development of Bloodâ€“Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. Journal of Medicinal Chemistry, 2016, 59, 7584-7597.	6.4	32
70	Effect of 3 Singleâ€Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catecholâ€Oâ€Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. Clinical Pharmacology in Drug Development, 2016, 5, 232-240.	1.6	29
71	A new PAMPA model using an in-house brain lipid extract for screening the bloodâ€“brain barrier permeability of drug candidates. International Journal of Pharmaceutics, 2016, 501, 102-111.	5.2	41
72	Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurology, The, 2016, 15, 154-165.	10.2	219

#	Article	IF	Citations
73	Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action. Pharmacology Research and Perspectives, 2015, 3, e00124.	2.4	66
74	Cardiac safety profile of etamicastat, a novel peripheral selective dopamine-Î²-hydroxylase inhibitor in non-human primates, human young and elderly healthy volunteers and hypertensive patients. IJC Metabolic & Endocrine, 2015, 7, 10-24.	0.5	4
75	Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. Clinical Pharmacology in Drug Development, 2015, 4, 454-462.	1.6	16
76	Carbamazepine and oxcarbazepine, but not eslicarbazepine, enhance excitatory synaptic transmission onto hippocampal CA1 pyramidal cells through an antagonist action at adenosine A1 receptors. Neuropharmacology, 2015, 93, 103-115.	4.1	22
77	Increased Arterial Blood Pressure and Vascular Remodeling in Mice Lacking Salt-Inducible Kinase 1 (SIK1). Circulation Research, 2015, 116, 642-652.	4.5	36
78	Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-Î²-hydroxylase: Comparison with nepicastat. European Journal of Pharmacology, 2015, 751, 50-58.	3.5	11
79	Cardiovascular safety pharmacology profile of etamicastat, a novel peripheral selective dopamine-ÃŸ-hydroxylase inhibitor. European Journal of Pharmacology, 2015, 750, 98-107.	3.5	2
80	Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partialâ€onset seizures: Results of a phase <scp>III</scp>, doubleâ€blind, randomized, placeboâ€controlled trial. Epilepsia, 2015, 56, 244-253.	5.1	101
81	Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. Xenobiotica, 2015, 45, 828-839.	1.1	9
82	Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine Î²-hydroxylase inhibition with etamicastat. Hypertension Research, 2015, 38, 605-612.	2.7	19
83	Carbamazepine aggravates absence seizures in two dedicated mouse models. Pharmacological Reports, 2015, 67, 986-995.	3.3	7
84	Short- and long-term regulation of intestinal Na⁺/H⁺exchange by Toll-like receptors TLR4 and TLR5. American Journal of Physiology - Renal Physiology, 2015, 309, G703-G715.	3.4	6
85	Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug. Brain, 2015, 138, 371-387.	7.6	72
86	Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I. Journal of Affective Disorders, 2015, 174, 70-82.	4.1	19
87	Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive rat. Hypertension Research, 2015, 38, 30-38.	2.7	21
88	Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: A comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology, 2015, 89, 122-135.	4.1	111
89	Metabolism of Opicapone, a Novel COMT Inhibitor: Characterization of In Vitro Glucuronidation. FASEB Journal, 2015, 29, 622.3.	0.5	0
90	Pharmacological Profile of Opicapone, a Third Generation Nitrocatechol COMT Inhibitor, in the Rat. FASEB Journal, 2015, 29, 771.15.	0.5	0

#	Article	IF	Citations
91	Pharmacological Profile of Opicapone in Wistar rat. , 2014, , 83.		4
92	Pharmacokinetic and Pharmacodynamic Properties of Etamicastat, a New DBH Inhibitor. , 2014, , 6.		0
93	Etamicastat, a new dopamine-ÃŸ-hydroxylase inhibitor, pharmacodynamics and metabolism in rat. European Journal of Pharmacology, 2014, 740, 285-294.	3.5	7
94	Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine Î²-hydroxylase inhibitor. British Journal of Clinical Pharmacology, 2014, 77, 1017-1026.	2.4	6
95	Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. BMC Neuroscience, 2014, 15, 134.	1.9	17
96	Effect of Opicapone, a New Catechol-O-Methyltransferase Inhibitor, in Levodopa Pharmakokinetics in the Cynomolgous Monkey. , 2014, , 79.		1
97	Novel COMT Inhibitors in Parkinson Disease. , 2014, , 78.		0
98	The effects of eslicarbazepine on persistent Na+ current and the role of the Na+ channel Î² subunits. Epilepsy Research, 2014, 108, 202-211.	1.6	30
99	Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. Neuropharmacology, 2014, 77, 334-341.	4.1	37
100	Medicinal Chemistry of Catechol O-Methyltransferase (COMT) Inhibitors and Their Therapeutic Utility. Journal of Medicinal Chemistry, 2014, 57, 8692-8717.	6.4	88
101	Effect of moderate liver impairment on the pharmacokinetics of opicapone. European Journal of Clinical Pharmacology, 2014, 70, 279-286.	1.9	27
102	Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. European Journal of Clinical Pharmacology, 2014, 70, 1059-1071.	1.9	58
103	Effect of eslicarbazepine acetate in the corneal kindling progression and the amygdala kindling model of temporal lobe epilepsy. Epilepsy Research, 2014, 108, 212-222.	1.6	24
104	Lack of Salt-Inducible Kinase 2 (SIK2) Prevents the Development of Cardiac Hypertrophy in Response to Chronic High-Salt Intake. PLoS ONE, 2014, 9, e95771.	2.5	16
105	Bioequivalence of Eslicarbazepine Acetate from Two Different Sources of its Active Product Ingredient in Healthy Subjects. Drugs in R and D, 2013, 13, 137-143.	2.2	2
106	Loss of oxidative stress tolerance in hypertension is linked to reduced catalase activity and increased c-Jun NH2-terminal kinase activation. Free Radical Biology and Medicine, 2013, 56, 112-122.	2.9	13
107	Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: New set of data for predictive in silico ADME models. Epilepsy Research, 2013, 107, 37-50.	1.6	30
108	Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. Epilepsia, 2013, 54, 1453-1461.	5.1	38

#	Article	IF	Citations
109	Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects. Clinical Pharmacokinetics, 2013, 52, 139-151.	3.5	79
110	Opicapone: a short lived and very long acting novel catecholâ€<scp>O</scp>â€methyltransferase inhibitor following multiple dose administration in healthy subjects. British Journal of Clinical Pharmacology, 2013, 76, 763-775.	2.4	76
111	Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. Epilepsy Research, 2013, 105, 368-376.	1.6	39
112	Etamicastat, a Novel Dopamine Î²-Hydroxylase Inhibitor: Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Hypertension. Clinical Therapeutics, 2013, 35, 1983-1996.	2.5	29
113	Identification of SLC26A transporters involved in the Clâ^'/HCO3â^' exchange in proximal tubular cells from WKY and SHR. Life Sciences, 2013, 93, 435-440.	4.3	7
114	Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: Results of a 1-year open-label extension study. Epilepsy Research, 2013, 103, 262-269.	1.6	74
115	Inhibitory effect of phenolic compounds from grape seeds (Vitis vinifera L.) on the activity of angiotensin I converting enzyme. LWT - Food Science and Technology, 2013, 54, 265-270.	5.2	15
116	Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. Epilepsy Research, 2013, 106, 244-249.	1.6	28
117	Steadyâ€state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia, 2013, 54, 108-116.	5.1	65
118	Efficacy and safety of eslicarbazepine acetate as addâ€on treatment in patients with focalâ€onset seizures: Integrated analysis of pooled data from doubleâ€blind phase III clinical studies. Epilepsia, 2013, 54, 98-107.	5.1	85
119	An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma. Analyst, The, 2013, 138, 2463.	3.5	9
120	Renal amino acid transport systems and essential hypertension. FASEB Journal, 2013, 27, 2927-2938.	0.5	34
121	Short- and Long-Term Regulation of Intestinal Na⁺/H⁺Exchange Activity Associated with TLR2 Receptor Activation Is Independent of Nuclear Factor-Î°B Signaling. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 453-464.	2.5	8
122	Evaluation of neurotoxic and neuroprotective pathways affected by antiepileptic drugs in cultured hippocampal neurons. Toxicology in Vitro, 2013, 27, 2193-2202.	2.4	8
123	N-Acetylation of Etamicastat, a Reversible Dopamine-Î²-Hydroxylase Inhibitor. Drug Metabolism and Disposition, 2013, 41, 2081-2086.	3.3	19
124	Catecholâ€Oâ€Methylâ€Transferase Inhibitors: Present Problems and Relevance of the New Ones. RSC Drug Discovery Series, 2013, , 83-109.	0.3	7
125	Identifications of Novel SNPs in Portuguese Essential Hypertensive Patients. FASEB Journal, 2013, 27, 874.14.	0.5	0
126	Analysis of MicroRNA Expression Profile in PBMCs of Hypertensive Patients. FASEB Journal, 2013, 27, 737.3.	0.5	0

#	Article	IF	Citations
127	Abstract 204: Sodium Sensing Network in Hypertension-Induced Cardiac Hypertrophy. Hypertension, 2013, 62, .	2.7	0
128	A chiral liquid chromatography method for the simultaneous determination of oxcarbazepine, eslicarbazepine, Râ€licarbazepine and other new chemical derivatives BIA 2â€“024, BIA 2â€“059 and BIA 2â€“265, in mouse plasma and brain. Biomedical Chromatography, 2012, 26, 384-392.	1.7	15
129	Increases in intracellular sodium activate transcription and gene expression via the salt-inducible kinase 1 network in an atrial myocyte cell line. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 303, H57-H65.	3.2	29
130	Saltâ€inducible kinase 1 regulates Eâ€cadherin expression and intercellular junction stability. FASEB Journal, 2012, 26, 3230-3239.	0.5	25
131	Singleâ€Dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Etamicastat (BIA 5â€“453), a New Dopamine Î²â€Hydroxylase Inhibitor, in Healthy Subjects. Journal of Clinical Pharmacology, 2012, 52, 156-170.	2.0	21
132	Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study. Journal of Clinical Pharmacology, 2012, 52, 222-233.	2.0	27
133	Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: A review. Analytica Chimica Acta, 2012, 710, 17-32.	5.4	32
134	Pharmacokinetics, Drug Interactions and Exposure-Response Relationship of Eslicarbazepine Acetate in Adult Patients with Partial-Onset Seizures. CNS Drugs, 2012, 26, 79-91.	5.9	58
135	New Insights into the Regulation of Na+,K+-ATPase by Ouabain. International Review of Cell and Molecular Biology, 2012, 294, 99-132.	3.2	43
136	Long-term food restriction attenuates age-related changes in the expression of renal aldosterone-sensitive sodium transporters in Wistar-Kyoto rats: A comparison with SHR. Experimental Gerontology, 2012, 47, 644-653.	2.8	3
137	Evaluation of the permeability and Pâ€glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique. Epilepsia, 2012, 53, 529-538.	5.1	45
138	Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia, 2012, 53, 935-946.	5.1	151
139	Computation of the binding affinities of catecholâ€Oâ€methyltransferase inhibitors: Multisubstate relative free energy calculations. Journal of Computational Chemistry, 2012, 33, 970-986.	3.3	51
140	Optimization of a Parallel Artificial Membrane Permeability Assay for the Fast and Simultaneous Prediction of Human Intestinal Absorption and Plasma Protein Binding of Drug Candidates: Application to Dibenz[b,f]azepine-5-Carboxamide Derivatives. Journal of Pharmaceutical Sciences, 2012, 101, 530-540.	3.3	33
141	Effect of Food on the Pharmacokinetic Profile of Etamicastat (BIA 5-453). Drugs in R and D, 2011, 11, 127-136.	2.2	7
142	Development and validation of an enantioselective liquid-chromatography/tandem mass spectrometry method for the separation and quantification of eslicarbazepine acetate, eslicarbazepine, R-licarbazepine and oxcarbazepine in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2611-2618.	2.3	23
143	Age-dependent effect of ouabain on renal Na+,K+-ATPase. Life Sciences, 2011, 88, 719-724.	4.3	4
144	In-vivo evaluation of prolonged release bilayer tablets of anti-Parkinson drugs in GÃ¶ttingen minipigs. Journal of Pharmacy and Pharmacology, 2011, 63, 780-785.	2.4	5

#	Article	IF	Citations
145	Does brain 3,4-dihydroxyphenylacetic acid reflect dopamine release?. Journal of Pharmacy and Pharmacology, 2011, 39, 127-129.	2.4	23
146	Age-related changes in the renal dopaminergic system and expression of renal amino acid transporters in WKY and SHR rats. Mechanisms of Ageing and Development, 2011, 132, 298-304.	4.6	12
147	Pharmacokinetics and Tolerability of Etamicastat Following Single and Repeated Administration in Elderly Versus Young Healthy Male Subjects: An Open-Label, Single-Center, Parallel-Group Study. Clinical Therapeutics, 2011, 33, 776-791.	2.5	15
148	Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Research, 2011, 96, 132-139.	1.6	66
149	Age-related changes in renal expression of oxidant and antioxidant enzymes and oxidative stress markers in male SHR and WKY rats. Experimental Gerontology, 2011, 46, 468-474.	2.8	28
150	LAT1 overexpression and function compensates downregulation of ASCT2 in an in vitro model of renal proximal tubule cell ageing. Molecular and Cellular Biochemistry, 2011, 349, 107-116.	3.1	3
151	A chiral HPLCâ€UV method for the quantification of dibenz[b,f]azepineâ€5â€carboxamide derivatives in mouse plasma and brain tissue: Eslicarbazepine acetate, carbamazepine and main metabolites. Journal of Separation Science, 2011, 34, 1391-1401.	2.5	15
152	Longâ€term regulation of Na⁺,K⁺â€ATPase in opossum kidney cells by ouabain. Journal of Cellular Physiology, 2011, 226, 2391-2397.	4.1	7
153	H2O2 stimulates Clâ^'/HCOâ€‰3â^' exchanger activity through oxidation of thiol groups in immortalized SHR renal proximal tubular epithelial cells. Journal of Cellular Biochemistry, 2011, 112, 3660-3665.	2.6	8
154	Hepatic UDP-Glucuronosyltransferase Is Responsible for Eslicarbazepine Glucuronidation. Drug Metabolism and Disposition, 2011, 39, 1486-1494.	3.3	17
155	Pharmacokinetics, Disposition, and Metabolism of [14C]-Nebicapone in Humans. Drug Metabolism Letters, 2010, 4, 149-162.	0.8	4
156	Enantioselective Assay for Therapeutic Drug Monitoring of Eslicarbazepine Acetate: No Interference With Carbamazepine and Its Metabolites. Therapeutic Drug Monitoring, 2010, 32, 512-516.	2.0	11
157	Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase. Journal of Medicinal Chemistry, 2010, 53, 3396-3411.	6.4	156
158	Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. Analytical and Bioanalytical Chemistry, 2010, 397, 1605-1615.	3.7	56
159	Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. Clinical Therapeutics, 2010, 32, 179-192.	2.5	35
160	Increased responsiveness to JNK1/2 mediates the enhanced H2O2-induced stimulation of Clâ^'/HCO3â^' exchanger activity in immortalized renal proximal tubular epithelial cells from the SHR. Biochemical Pharmacology, 2010, 80, 913-919.	4.4	7
161	Binding of licarbazepine enantiomers to mouse and human plasma proteins. Biopharmaceutics and Drug Disposition, 2010, 31, 362-366.	1.9	10
162	Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Research, 2010, 89, 278-285.	1.6	166

#	Article	IF	Citations
163	Longâ€term efficacy and safety of eslicarbazepine acetate: Results of a 1â€year openâ€label extension study in partialâ€onset seizures in adults with epilepsy. Epilepsia, 2010, 51, 1963-1969.	5.1	92
164	Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurologica Scandinavica, 2010, 121, 257-264.	2.1	41
165	Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor. Current Medical Research and Opinion, 2010, 26, 1097-1108.	1.9	5
166	Comments on the Eslicarbazepine Acetate Section of the Article â€˜Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medicationsâ€™. Pharmaceuticals, 2010, 3, 3629-3632.	3.8	1
167	The Chemistry of Catechol-O-Methyltransferase Inhibitors. International Review of Neurobiology, 2010, 95, 119-162.	2.0	19
168	Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Current Medical Research and Opinion, 2010, 26, 1355-1362.	1.9	31
169	Dopamine and G protein-coupled receptor kinase 4 in the kidney: Role in blood pressure regulation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 1259-1267.	3.8	90
170	Role of H2O2 on the kinetics of low-affinity high-capacity Na+-dependent alanine transport in SHR proximal tubular epithelial cells. Biochemical and Biophysical Research Communications, 2010, 398, 553-558.	2.1	2
171	Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. Epilepsy and Behavior, 2010, 18, 366-373.	1.7	37
172	A Doubleâ€Blind, Randomized, Placebo and Activeâ€Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease. CNS Neuroscience and Therapeutics, 2010, 16, 337-347.	3.9	21
173	Renal aging in WKY rats: Changes in Na+,K+-ATPase function and oxidative stress. Experimental Gerontology, 2010, 45, 977-983.	2.8	11
174	Safety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine-Î²-Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy Subjects. Drugs in R and D, 2010, 10, 225-242.	2.2	23
175	Aging increases Oxidative Stress and Renal Expression of Oxidant and Antioxidant Enzymes that Are Associated with an Increased Trend in Systolic Blood Pressure. Oxidative Medicine and Cellular Longevity, 2009, 2, 138-145.	4.0	59
176	Regulation of amino acid transporters in the rat remnant kidney. Nephrology Dialysis Transplantation, 2009, 24, 2058-2067.	0.7	9
177	Pharmacokineticâ€”pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: A single-center, phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects. Clinical Therapeutics, 2009, 31, 2258-2271.	2.5	13
178	Species differences in pharmacokinetic and pharmacodynamic properties of nebicapone. Biochemical Pharmacology, 2009, 78, 1043-1051.	4.4	10
179	Protein cytoskeleton and overexpression of Na⁺,K⁺â€ATPase in opossum kidney cells. Journal of Cellular Physiology, 2009, 221, 318-324.	4.1	10
180	Pharmacokinetic and safety profile of transâ€resveratrol in a rising multipleâ€dose study in healthy volunteers. Molecular Nutrition and Food Research, 2009, 53, S7-15.	3.3	363

#	Article	IF	Citations
181	Efficacy and safety of 800 and 1200â€ƒmg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurologica Scandinavica, 2009, 120, 281-287.	2.1	155
182	Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partialâ€onset seizures: A randomized, doubleâ€blind, placeboâ€controlled, parallelâ€group phase III study. Epilepsia, 2009, 50, 454-463.	5.1	241
183	Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundamental and Clinical Pharmacology, 2009, 23, 509-514.	1.9	26
184	Pharmacokinetics of Transâ€resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects. Journal of Clinical Pharmacology, 2009, 49, 1477-1482.	2.0	98
185	Interpersonal Values of Healthy Subjects Who Volunteer for Phase I Clinical Trials. Pharmaceutical Medicine, 2009, 23, 299-303.	1.9	1
186	Dopamine β-Monooxygenase: Mechanism, Substrates and Inhibitors. Current Enzyme Inhibition, 2009, 5, 27-43.	0.4	25
187	Regulation of Renal LAT2 and 4F2hc Expression by Aldosterone. Journal of Epithelial Biology & Pharmacology, 2009, 2, 36-43.	1.2	3
188	Oxidative stress and the genomic regulation of aldosterone-stimulated NHE1 activity in SHR renal proximal tubular cells. Molecular and Cellular Biochemistry, 2008, 310, 191-201.	3.1	39
189	Genomic regulation of intestinal amino acid transporters by aldosterone. Molecular and Cellular Biochemistry, 2008, 313, 1-10.	3.1	11
190	Oxidative stress plays a permissive role in Î±2-adrenoceptor-mediated events in immortalized SHR proximal tubular epithelial cells. Molecular and Cellular Biochemistry, 2008, 315, 31-39.	3.1	13
191	Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. European Journal of Clinical Pharmacology, 2008, 64, 267-273.	1.9	102
192	Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events. European Journal of Clinical Pharmacology, 2008, 64, 575-582.	1.9	35
193	Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. European Journal of Clinical Pharmacology, 2008, 64, 961-966.	1.9	6
194	Stereoselective disposition of Sâ€and Râ€licarbazepine in mice. Chirality, 2008, 20, 796-804.	2.6	18
195	A new approach on the purification of recombinant human soluble catechol-O-methyltransferase from an Escherichia coli extract using hydrophobic interaction chromatography. Journal of Chromatography A, 2008, 1177, 287-296.	3.7	20
196	Oxidative stress and Î±₁â€adrenoceptorâ€mediated stimulation of the Cl^{â^’}/HCO₃^{â^’} exchanger in immortalized SHR proximal tubular epithelial cells. British Journal of Pharmacology, 2008, 153, 1445-1455.	5.4	17
197	Disposition of eslicarbazepine acetate in the mouse after oral administration. Fundamental and Clinical Pharmacology, 2008, 22, 529-536.	1.9	12
198	Short-term regulation of the Clâ^’/HCO3â^’ exchanger in immortalized SHR proximal tubular epithelial cells. Biochemical Pharmacology, 2008, 75, 2224-2233.	4.4	7

#	Article	IF	Citations
199	Pharmacokinetics, Efficacy, and Tolerability of Eslicarbazepine Acetate in Children and Adolescents With Epilepsy. Journal of Clinical Pharmacology, 2008, 48, 966-977.	2.0	62
200	The Role of Socioeconomic Conditions and Psychological Factors in the Willingness to Volunteer for Phase I Studies. Pharmaceutical Medicine, 2008, 22, 367-374.	1.9	3
201	Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200Âmg/50Âmg. Drugs in R and D, 2008, 9, 435-446.	2.2	4
202	Dosage Form Proportionality andÂFood Effect of the FinalÂTabletÂFormulation ofÂEslicarbazepine Acetate. Drugs in R and D, 2008, 9, 447-454.	2.2	17
203	H ₂ O ₂ Stimulation of the Cl ^{â^'} /HCO ₃ ^{â^'} Exchanger by Angiotensin II and Angiotensin II Type 1 Receptor Distribution in Membrane Microdomains. Hypertension, 2008, 51, 1332-1338.	2.7	26
204	Effects of Nebicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity, and Motor Fluctuations in Patients with Parkinson Disease. Clinical Neuropharmacology, 2008, 31, 2-18.	0.7	30
205	Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. Journal of Clinical Investigation, 2008, 118, 2180-9.	8.2	72
206	Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. Journal of Clinical Investigation, 2008, 118, 2986-2986.	8.2	181
207	Underexpression of the Na+-dependent neutral amino acid transporter ASCT2 in the spontaneously hypertensive rat kidney. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R538-R547.	1.8	16
208	High-salt intake and the renal expression of amino acid transporters in spontaneously hypertensive rats. American Journal of Physiology - Renal Physiology, 2007, 292, F1452-F1463.	2.7	27
209	Reactive oxygen species and the regulation of renal Na⁺-K⁺-ATPase in opossum kidney cells. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R1764-R1770.	1.8	23
210	Activity and Regulation of Na + -HCO 3 â^' Cotransporter in Immortalized Spontaneously Hypertensive Rat and Wistarâ€"Kyoto Rat Proximal Tubular Epithelial Cells. Hypertension, 2007, 49, 1186-1193.	2.7	17
211	Overexpression of Non-Functional LAT1/4F2hc in Renal Proximal Tubular Epithelial Cells from the Spontaneous Hypertensive Rat. Cellular Physiology and Biochemistry, 2007, 20, 535-548.	1.6	4
212	Short-term effect on intestinal epithelial Na+/H+ exchanger by Gi$\hat{l}$±1,2-coupled 5-HT1A and Gq/11-coupled 5-HT2 receptors. Life Sciences, 2007, 81, 560-569.	4.3	7
213	Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharmaceutics and Drug Disposition, 2007, 28, 249-256.	1.9	50
214	Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics, 2007, 4, 88-96.	4.4	180
215	Catecholâ€Oâ€methyltransferase and Its Inhibitors in Parkinson's Disease. CNS Neuroscience & Therapeutics, 2007, 13, 352-379.	4.0	166
216	Eslicarbazepine Acetate: A Double-blind, Add-on, Placebo-controlled Exploratory Trial in Adult Patients with Partial-onset Seizures. Epilepsia, 2007, 48, 497-504.	5.1	119

#	Article	IF	Citations
217	Effects of cyclic hydrostatic pressure on the brain biogenic amines concentrations in the flounder, Platichthys flesus. General and Comparative Endocrinology, 2007, 153, 385-389.	1.8	18
218	Why healthy subjects volunteer for phase I studies and how they perceive their participation?. European Journal of Clinical Pharmacology, 2007, 63, 1085-1094.	1.9	65
219	Organ specific underexpression renal of Na+-dependent B0AT1 in the SHR correlates positively with overexpression of NHE3 and salt intake. Molecular and Cellular Biochemistry, 2007, 306, 9-18.	3.1	8
220	Ouabain induced hypertension and Na ⁺ ,K ⁺ â€ATPase in Wistar rats. FASEB Journal, 2007, 21, A1363.	0.5	1
221	Comparative Study of ortho- and meta-Nitrated Inhibitors of Catechol-O-methyltransferase: Interactions with the Active Site and Regioselectivity of O-Methylation. Molecular Pharmacology, 2006, 70, 143-153.	2.3	48
222	Synthesis and Biological Evaluation of Novel, Peripherally Selective Chromanyl Imidazolethione-Based Inhibitors of Dopamine Î²-Hydroxylase. Journal of Medicinal Chemistry, 2006, 49, 1191-1197.	6.4	59
223	Increases in transepithelial vectorial Na+ transport facilitates Na+-dependent l-DOPA transport in renal OK cells. Life Sciences, 2006, 79, 723-729.	4.3	9
224	Human Metabolism of Nebicapone (BIA 3-202), a Novel Catechol-O-Methyltransferase Inhibitor: Characterization of in Vitro Glucuronidation. Drug Metabolism and Disposition, 2006, 34, 1856-1862.	3.3	22
225	Effects of cyclic and constant hydrostatic pressure on norepinephrine and epinephrine levels in the brain of flounder. Journal of Fish Biology, 2006, 68, 1300-1307.	1.6	11
226	Intestinal 5-Hydroxytryptamine and Mast Cell Infiltration in Rat Experimental Colitis. Digestive Diseases and Sciences, 2006, 51, 495-501.	2.3	15
227	Dopamine D2 Receptor Polymorphisms in Inflammatory Bowel Disease and the Refractory Response to Treatment. Digestive Diseases and Sciences, 2006, 51, 2039-2044.	2.3	37
228	Overexpression of Na+/K+-ATPase Parallels the Increase in Sodium Transport and Potassium Recycling in an In Vitro Model of Proximal Tubule Cellular Ageing. Journal of Membrane Biology, 2006, 212, 163-175.	2.1	20
229	Upregulation of apical NHE3 in renal OK cells overexpressing the rodent Î±1-subunit of the Na+ pump. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 290, R1142-R1150.	1.8	10
230	Angiotensin-II Type 1 Receptorâ€“Mediated Hypertension in D 4 Dopamine Receptorâ€–Deficient Mice. Hypertension, 2006, 47, 288-295.	2.7	62
231	Dopamine D₁-like Receptor-Mediated Inhibition of Cl⁻/HCO₃⁻ Exchanger Activity in Rat Intestinal Epithelial IEC-6 Cells is Regulated by G Protein-Coupled Receptor Kinase 6 (GRK 6). Cellular Physiology and Biochemistry, 2006, 18, 347-360.	1.6	15
232	Effect of Saline Load and Metoclopramide on the Renal Dopaminergic System in Patients with Heart Failure and Healthy Controls. Journal of Cardiovascular Pharmacology, 2005, 45, 197-203.	1.9	14
233	Longâ€term Effect of Convulsive Behavior on the Density of Adenosine A₁ and A_{2A} Receptors in the Rat Cerebral Cortex. Epilepsia, 2005, 46, 159-165.	5.1	87
234	Regional intestinal adaptations in Na+,K+-ATPase in experimental colitis and the contrasting effects of interferon-gamma. Acta Physiologica Scandinavica, 2005, 183, 191-199.	2.2	10

#	Article	IF	Citations
235	Expression and function of LAT1, a neutral amino acid exchanger, in renal porcine epithelial cell line LLC-PK1. Acta Physiologica Scandinavica, 2005, 185, 71-78.	2.2	9
236	Salt sensitivity of blood pressure in patients with psoriasis on ciclosporin therapy. British Journal of Dermatology, 2005, 152, 773-776.	1.5	7
237	Signaling of short- and long-term regulation of intestinal epithelial type 1 Na+ /H+ exchanger by interferon-Î³. British Journal of Pharmacology, 2005, 145, 93-103.	5.4	21
238	Interferon-Î³-induced STAT1-mediated membrane retention of NHE1 and associated proteins ezrin, radixin and moesin in HT-29 cells. Biochemical Pharmacology, 2005, 70, 1312-1319.	4.4	14
239	Expression of LAT1 and LAT2 amino acid transporters in human and rat intestinal epithelial cells. Amino Acids, 2005, 29, 229-233.	2.7	50
240	Apical and basolateral 4F2hc and the amino acid exchange of L-DOPA in renal LLC-PK1 cells. Amino Acids, 2005, 29, 213-219.	2.7	3
241	Crystallization and preliminary X-ray diffraction studies of a catechol-O-methyltransferase/inhibitor complex. Acta Crystallographica Section F: Structural Biology Communications, 2005, 61, 118-120.	0.7	7
242	Single-Dose and Steady-State Pharmacokinetics of Eslicarbazepine Acetate (BIA 2-093) in Healthy Elderly and Young Subjects. Journal of Clinical Pharmacology, 2005, 45, 1062-1066.	2.0	104
243	Effect of Food on the Pharmacokinetic Profile of Eslicarbazepine Acetate (BIA 2-093). Drugs in R and D, 2005, 6, 201-206.	2.2	48
244	Eslicarbazepine Acetate (BIA 2-093). Drugs in R and D, 2005, 6, 253-260.	2.2	19
245	Bioavailability and Bioequivalence of??Two Enteric-Coated Formulations of??Omeprazole in Fasting and Fed Conditions. Clinical Drug Investigation, 2005, 25, 391-399.	2.2	26
246	Synthesis and Biological Evaluation of a Novel Series of â€œOrtho-Nitratedâ€•Inhibitors of Catechol-O-methyltransferase. Journal of Medicinal Chemistry, 2005, 48, 8070-8078.	6.4	23
247	GiÎ±3 protein-coupled dopamine D3 receptor-mediated inhibition of renal NHE3 activity in SHR proximal tubular cells is a PLC-PKC-mediated event. American Journal of Physiology - Renal Physiology, 2004, 287, F1059-F1066.	2.7	36
248	Defective D1-like receptor-mediated inhibition of the Clâ¯/HCO3â¯ exchanger in immortalized SHR proximal tubular epithelial cells. American Journal of Physiology - Renal Physiology, 2004, 286, F1120-F1126.	2.7	54
249	Renal Dopamine and Salt Sensitivity of Blood Pressure in IgA Nephropathy. Kidney and Blood Pressure Research, 2004, 27, 78-87.	2.0	4
250	Distinct Signalling Cascades Downstream to G_sÎ± Coupled Dopamine D₁-like NHE3 Inhibition in Rat and Opossum Renal Epithelial Cells. Cellular Physiology and Biochemistry, 2004, 14, 91-100.	1.6	27
251	Cloning and gene silencing of LAT2, the Lâ€3,4â€dihydroxyphenylalanine (lâ€ÐOPA) transporter, in pig renal LLCâ€PK epithelial cells. FASEB Journal, 2004, 18, 1489-1498.	0.5	22
252	Involvement of G protein-coupled receptor kinase 4 and 6 in rapid desensitization of dopamine D1 receptor in rat IEC-6 intestinal epithelial cells. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 287, R772-R779.	1.8	18

#	Article	IF	Citations
253	The effect of dietary sodium restriction on neurohumoral activity and renal dopaminergic response in patients with heart failure. European Journal of Heart Failure, 2004, 6, 593-599.	7.1	65
254	Decreased availability of intestinal dopamine in transmural colitis may relate to inhibitory effects of interferon-gamma upon L-DOPA uptake. Acta Physiologica Scandinavica, 2004, 180, 379-386.	2.2	43
255	Over-expression of renal LAT1 and LAT2 and enhanced L-DOPA uptake in SHR immortalized renal proximal tubular cells. Kidney International, 2004, 66, 216-226.	5.2	42
256	Neurotoxicity Induced by Antiepileptic Drugs in Cultured Hippocampal Neurons: A Comparative Study between Carbamazepine, Oxcarbazepine, and Two New Putative Antiepileptic Drugs, BIA 2-024 and BIA 2-093. Epilepsia, 2004, 45, 1498-1505.	5.1	53
257	Dopamine D₃ receptorâ€mediated inhibition of Na⁺/H⁺ exchanger activity in normotensive and spontaneously hypertensive rat proximal tubular epithelial cells. British Journal of Pharmacology, 2004, 142, 1343-1353.	5.4	37
258	Dopamine acutely decreases type 3 Na+/H+ exchanger activity in renal OK cells through the activation of protein kinases A and C signalling cascades. European Journal of Pharmacology, 2004, 488, 51-59.	3.5	33
259	Synthesis, Biological Evaluation, and Molecular Modeling Studies of a Novel, Peripherally Selective Inhibitor of Catechol-O-methyltransferase. Journal of Medicinal Chemistry, 2004, 47, 6207-6217.	6.4	37
260	High- and low-affinity transport of l-leucine and l-DOPA by the hetero amino acid exchangers LAT1 and LAT2 in LLC-PK1 renal cells. American Journal of Physiology - Renal Physiology, 2004, 287, F252-F261.	2.7	33
261	Intestinal Na+ -K+ -ATPase activity and molecular events downstream of interferon-Î³ receptor stimulation. British Journal of Pharmacology, 2004, 142, 1281-1292.	5.4	14
262	Safety, Tolerability, and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic, in a Rising Multiple-Dose Study in Young Healthy Humans. Journal of Clinical Pharmacology, 2004, 44, 906-918.	2.0	57
263	Pharmacokineticâ€“Pharmacodynamic Interaction Between BIA 3-202, a Novel COMT Inhibitor, and Levodopa/Carbidopa. Clinical Neuropharmacology, 2004, 27, 17-24.	0.7	15
264	Effects of enalapril and imidapril in the capsaicin cough challenge test and spirometry parameters in healthy volunteers. Therapy: Open Access in Clinical Medicine, 2004, 1, 223-230.	0.2	0
265	Pharmacokinetic?pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. European Journal of Clinical Pharmacology, 2003, 59, 603-609.	1.9	22
266	Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor. European Journal of Pharmacology, 2003, 460, 163-170.	3.5	26
267	Catechol-O-methyltransferase Inhibition in Erythrocytes and Liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone). Basic and Clinical Pharmacology and Toxicology, 2003, 92, 272-278.	0.0	14
268	Decrease of adenosine A₁ receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. European Journal of Neuroscience, 2003, 18, 820-828.	2.6	108
269	Dopamine D2 -like receptor-mediated opening of K+ channels in opossum kidney cells. British Journal of Pharmacology, 2003, 138, 968-976.	5.4	7
270	Short- and long-term regulation of intestinal Na+/H+ exchanger by IFN-Î³ in Caco-2 cells. Gastroenterology, 2003, 124, A313.	1.3	1

#	Article	IF	Citations
271	Differential substrate specificity of monoamine oxidase in the rat heart and renal cortex. Life Sciences, 2003, 73, 955-967.	4.3	4
272	BIA 3-202, a Novel Catechol-O-Methyltransferase Inhibitor, Reduces the Peripheral O-Methylation of L-DOPA and Enhances Its Availability to the Brain. Pharmacology, 2003, 68, 29-37.	2.2	12
273	Pharmacokinetics and Pharmacodynamics of BIA 3-202, a Novel COMT Inhibitor, during First Administration to Humans. Drugs in R and D, 2003, 4, 207-217.	2.2	19
274	Safety, Tolerability and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic Agent, during First Administration to Humans. Drugs in R and D, 2003, 4, 269-284.	2.2	35
275	Molecular Modeling and Metabolic Studies of The Interaction of Catechol-O-Methyltransferase and a New Nitrocatechol Inhibitor. Drug Metabolism and Disposition, 2003, 31, 250-258.	3.3	39
276	Organ-Specific Overexpression of Renal LAT2 and Enhanced Tubular l -DOPA Uptake Precede the Onset of Hypertension. Hypertension, 2003, 42, 613-618.	2.7	29
277	Pharmacokinetic and Pharmacodynamic Profiles of BIA 3-202, a Novel Catechol-O-Methyltransferase (COMT) Inhibitor, during Multiple-Dose Administration to Healthy Subjects. Journal of Clinical Pharmacology, 2003, 43, 1350-1360.	2.0	13
278	Metabolism of 10,11-dihydro-10-hydroxyimino-5H-dibenz/b, Æ' /azepine-5-carboxamide, a potent anti-epileptic drug. Xenobiotica, 2002, 32, 131-140.	1.1	8
279	INTESTINAL DOPAMINERGIC ACTIVITY IN OBESE AND LEAN ZUCKER RATS: RESPONSE TO HIGH SALT INTAKE. Clinical and Experimental Hypertension, 2002, 24, 383-396.	1.3	12
280	D₂-like receptor-mediated inhibition of Na⁺-K⁺-ATPase activity is dependent on the opening of K⁺channels. American Journal of Physiology - Renal Physiology, 2002, 283, F114-F123.	2.7	23
281	Role of cAMP-PKA-PLC signaling cascade on dopamine-induced PKC-mediated inhibition of renal Na+-K+-ATPase activity. American Journal of Physiology - Renal Physiology, 2002, 282, F1084-F1096.	2.7	54
282	Synthesis of 1-(3,4-Dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and Derivatives as Potent and Long-Acting Peripheral Inhibitors of Catechol-O-methyltransferase. Journal of Medicinal Chemistry, 2002, 45, 685-695.	6.4	59
283	Kinetics and Crystal Structure of Catechol-O-Methyltransferase Complex with Co-Substrate and a Novel Inhibitor with Potential Therapeutic Application. Molecular Pharmacology, 2002, 62, 795-805.	2.3	81
284	Transport of the organic cations gonyautoxin 2/3 epimers, a paralytic shellfish poison toxin, through the human and rat intestinal epitheliums. Toxicon, 2002, 40, 1389-1397.	1.6	27
285	The renal dopaminergic system, neurohumoral activation, and sodium handling in heart failure. American Heart Journal, 2002, 143, 391-397.	2.7	14
286	The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. Neurochemistry International, 2002, 40, 435-440.	3.8	49
287	L-Type Amino Acid Transporters in Two Intestinal Epithelial Cell Lines Function as Exchangers with Neutral Amino Acids. Journal of Nutrition, 2002, 132, 733-738.	2.9	32
288	Expression and function of sodium transporters in two opossum kidney cell clonal sublines. American Journal of Physiology - Renal Physiology, 2002, 283, F73-F85.	2.7	12

#	Article	IF	Citations
289	Na⁺/H⁺ Exchanger Activity and Dopamine D₁-Like Receptor Function in two Opossum Kidney Cell Clonal Sublines. Cellular Physiology and Biochemistry, 2002, 12, 259-268.	1.6	13
290	Mice Lacking D₅Dopamine Receptors Have Increased Sympathetic Tone and Are Hypertensive. Journal of Neuroscience, 2002, 22, 10801-10810.	3.6	141
291	The l-3,4-dihydroxyphenylalanine transporter in human and rat epithelial intestinal cells is a type 2 hetero amino acid exchanger. European Journal of Pharmacology, 2002, 441, 127-135.	3.5	24
292	Modulation of insulin transport in rat brain microvessel endothelial cells by an ecto-phosphatase activity. Journal of Cellular Biochemistry, 2002, 84, 389-400.	2.6	29
293	Regulation of [3 H]MPP + transport by phosphorylation/dephosphorylation pathways in RBE4 cells: role of ecto-alkaline phosphatase. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 365, 349-356.	3.0	20
294	Na+-Independent Transporters, LAT-2 and b0,+, Exchange L-DOPA with Neutral and Basic Amino Acids in Two Clonal Renal Cell Lines. Journal of Membrane Biology, 2002, 186, 63-80.	2.1	32
295	Dopamine-induced inhibition of Na+-K+-ATPase activity requires integrity of actin cytoskeleton in opossum kidney cells. Acta Physiologica Scandinavica, 2002, 175, 93-101.	2.2	14
296	Regulation of apical transporter ofL-DOPA in human intestinal Caco-2 cells. Acta Physiologica Scandinavica, 2002, 175, 103-111.	2.2	13
297	Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L -3,4-dihydroxyphenylalanine (L -DOPA) and dopamine. British Journal of Pharmacology, 2002, 137, 1305-1313.	5.4	105
298	Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Digestive Diseases and Sciences, 2002, 47, 216-224.	2.3	175
299	Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochemical Research, 2002, 27, 121-130.	3.3	250
300	Relative Bioavailability of Two Enteric-Coated Formulations of Omeprazole following Repeated Doses in Healthy Volunteers. Clinical Drug Investigation, 2001, 21, 203-210.	2.2	1
301	Expression and Characterization of Rat Soluble Catechol-O-methyltransferase Fusion Protein. Protein Expression and Purification, 2001, 23, 106-112.	1.3	16
302	Salt intake and intestinal dopaminergic activity in adult and old Fischer 344 rats. Life Sciences, 2001, 69, 1957-1968.	4.3	7
303	Comparative study on sodium transport and Na+,K+-ATPase activity in Caco-2 and rat jejunal epithelial cells. Life Sciences, 2001, 69, 1969-1981.	4.3	13
304	Altered dopaminergic transmission in the anorexic anx/anx mouse striatum. NeuroReport, 2001, 12, 2737-2741.	1.2	16
305	Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. Clinical Science, 2001, 100, 557-566.	4.3	22
306	Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. Clinical Science, 2001, 100, 557.	4.3	12

#	Article	IF	Citations
307	Transport of [3 H]MPP + in an immortalized rat brain microvessel endothelial cell line (RBE 4). Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 1-10.	3.0	10
308	Synthesis, anticonvulsant properties and pharmacokinetic profile of novel 10,11-dihydro-10-oxo-5H-dibenz/b,f/azepine-5-carboxamide derivatives. European Journal of Medicinal Chemistry, 2001, 36, 227-236.	5.5	22
309	D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors. Kidney International, 2001, 59, 1683-1694.	5.2	25
310	Interaction of the Novel Anticonvulsant, BIA 2-093, with Voltage-Gated Sodium Channels: Comparison with Carbamazepine. Epilepsia, 2001, 42, 600-608.	5.1	95
311	INHIBITION OF CALCIUM-INDEPENDENT LUMINAL UPTAKE OF L-DOPA BY CALMODULIN ANTAGONISTS IN IMMORTALIZED RAT CAPILLARY CEREBRAL ENDOTHELIAL CELLS. Cell Biology International, 2001, 25, 245-252.	3.0	3
312	Crystallization and preliminary crystallographic characterization of catechol-O-methyltransferase in complex with its cosubstrate and an inhibitor. Acta Crystallographica Section D: Biological Crystallography, 2001, 57, 906-908.	2.5	7
313	Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(â^')-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Research, 2001, 44, 197-206.	1.6	93
314	Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels11Abbreviations: AED, antiepileptic drug; CBZ, carbamazepine; OXC, oxcarbazepine; and 4-AP, 4-aminopyridine.. Biochemical Pharmacology, 2001, 61, 1271-1275.	4.4	45
315	BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of l-DOPA to the brain and reduces its O-methylation. European Journal of Pharmacology, 2001, 420, 27-32.	3.5	20
316	Heart failure, aging, and renal synthesis of dopamine. American Journal of Kidney Diseases, 2001, 38, 502-509.	1.9	11
317	Renal synthesis of dopamine in asymptomatic post-infarction left ventricular systolic dysfunction. Clinical Science, 2000, 99, 195-200.	4.3	7
318	Renal synthesis of dopamine in asymptomatic post-infarction left ventricular systolic dysfunction. Clinical Science, 2000, 99, 195.	4.3	4
319	Effect of salt intake on jejunal dopamine, Na+ ,K+ -ATPase activity and electrolyte transport. Acta Physiologica Scandinavica, 2000, 168, 225-231.	2.2	24
320	Response of jejunal Na⁺, K⁺â€ATPase to 5â€hydroxytryptamine in young and adult rats: Effect of fasting and refeeding. Acta Physiologica Scandinavica, 2000, 169, 167-172.	2.2	5
321	Ontogenic aspects of D1 receptor coupling to G proteins and regulation of rat jejunal Na+ , K+ ATPase activity and electrolyte transport. British Journal of Pharmacology, 2000, 129, 573-581.	5.4	20
322	The O-methylated derivative of l-DOPA, 3-O-methyl-l-DOPA, fails to inhibit neuronal and non-neuronal aromatic l-amino acid decarboxylase. Brain Research, 2000, 863, 293-297.	2.2	16
323	Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024. European Journal of Pharmacology, 2000, 406, 191-201.	3.5	45
324	SALT INTAKE AND SENSITIVITY OF INTESTINAL AND RENAL NA⁺-K⁺ATPase TO INHIBITION BY DOPAMINE IN SPONTANEOUS HYPERTENSIVE AND WISTAR-KYOTO RATS. Clinical and Experimental Hypertension, 2000, 22, 455-469.	1.3	26

#	Article	IF	Citations
325	Kinetics of Rat Brain and Liver Solubilized Membrane-Bound Catechol-O-Methyltransferase. Archives of Biochemistry and Biophysics, 2000, 384, 361-367.	3.0	21
326	Ca2+/calmodulin mediated pathways regulate the uptake of L-DOPA in mouse neuroblastoma neuro 2A cells. Life Sciences, 2000, 67, 3209-3220.	4.3	6
327	The dopamine antagonist Sch 23390 reverses dizocilpine-induced blockade of cocaine sensitization. Neuropharmacology, 2000, 39, 1645-1652.	4.1	3
328	RENAL DOPAMINERGIC MECHANISMS IN RENAL PARENCHYMAL DISEASES, HYPERTENSION, AND HEART FAILURE. Clinical and Experimental Hypertension, 2000, 22, 251-268.	1.3	12
329	Aging, High Salt Intake, and Renal Dopaminergic Activity in Fischer 344 Rats. Hypertension, 1999, 34, 666-672.	2.7	63
330	P-glycoprotein phosphorylation/dephosphorylation and cellular accumulation of L-DOPA in LLC-GA5 Col300 cells. Autonomic and Autacoid Pharmacology, 1999, 19, 173-179.	0.6	4
331	Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain Research, 1999, 821, 69-78.	2.2	60
332	l-DOPA transport properties in an immortalised cell line of rat capillary cerebral endothelial cells, RBE 4. Brain Research, 1999, 829, 143-150.	2.2	82
333	Anticonvulsant and Sodium Channel-Blocking Properties of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine-5-carboxamide Derivatives. Journal of Medicinal Chemistry, 1999, 42, 2582-2587.	6.4	189
334	Interaction between l-DOPA and 3-O-methyl-l-DOPA for transport in immortalised rat capillary cerebral endothelial cells. Neuropharmacology, 1999, 38, 1371-1380.	4.1	40
335	Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology, 1999, 38, 1349-1359.	4.1	79
336	Deficiency of renal dopaminergic-dependent natriuretic response to acute sodium load in black salt-sensitive subjects in contrast to salt-resistant subjects. Journal of Hypertension, 1999, 17, 1995-2001.	0.5	36
337	Acute Hypotensive, Natriuretic, and Hormonal Effects of Nifedipine in Salt-Sensitive and Salt-Resistant Black Normotensive and Hypertensive Subjects. Journal of Cardiovascular Pharmacology, 1999, 34, 346-353.	1.9	14
338	Evidence for the involvement of Pâ€glycoprotein on the extrusion of taken up L â€DOPA in cyclosporine A treated LLCâ€PK 1 cells. British Journal of Pharmacology, 1998, 123, 13-22.	5.4	10
339	Î±2-Adrenoceptors mediate the effect of dopamine on adult rat jejunal electrolyte transport. European Journal of Pharmacology, 1998, 356, 59-65.	3.5	20
340	l-3,4-Dihydroxyphenylalanine (l-DOPA) secreted by oyster (Crassostrea gigas) mantle cells: functional aspects. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 1998, 120, 709-713.	1.6	7
341	l-3,4-dihydroxyphenylalanine and l-5-hydroxytryptophan share the same transporter in Opossum kidney cells. International Journal of Biochemistry and Cell Biology, 1998, 30, 243-250.	2.8	0
342	The activity of MAO A and B in rat renal cells and tubules. Life Sciences, 1998, 62, 727-737.	4.3	20

#	Article	IF	Citations
343	Caco-2 cells in culture synthesize and degrade dopamine and 5-hydroxytryptamine: A comparison with rat jejunal epithelial cells. Life Sciences, 1998, 64, 69-81.	4.3	15
344	Reduced Urinary Excretion of Dopamine and Metabolites in Chronic Renal Parenchymal Disease. Kidney and Blood Pressure Research, 1998, 21, 59-65.	2.0	26
345	Rat Liver Catechol-O-Methyltransferase Kinetics and Assay Methodology. Journal of Enzyme Inhibition and Medicinal Chemistry, 1998, 13, 473-483.	0.5	5
346	Renal dopaminergic system in nephrotic syndrome and after remission. Nephrology Dialysis Transplantation, 1998, 13, 2559-2562.	0.7	2
347	109 Molecular and kinetic characterization of monoamine oxidases in the rat heart. Biochemical Society Transactions, 1998, 26, S392-S392.	3.4	0
348	Dopamine-dependent inhibition of jejunal Na⁺-K⁺-ATPase during high-salt diet in young but not in adult rats. American Journal of Physiology - Renal Physiology, 1998, 275, G1317-G1323.	3.4	29
349	Renal and Intestinal Autocrine Monoaminergic Systems: Dopamine Versus 5-hydroxytryptamine. Clinical and Experimental Hypertension, 1997, 19, 43-58.	1.3	26
350	Assessment of renal dopaminergic system activity during the recovery of renal function in human kidney transplant recipients. Nephrology Dialysis Transplantation, 1997, 12, 2667-2672.	0.7	12
351	88 Unusual pattern of Î²-phenylethylamine deamination in the rat heart. Biochemical Society Transactions, 1997, 25, S622-S622.	3.4	1
352	Nonneuronal Dopamine. Advances in Pharmacology, 1997, 42, 866-869.	2.0	5
353	Short-Term vs. Sustained Inhibition of Proximal Tubule Na, K-ATPase Activity by Dopamine: Cellular Mechanisms. Clinical and Experimental Hypertension, 1997, 19, 73-86.	1.3	21
354	Uptake of l-3,4-dihydroxyphenylalanine and dopamine formation in cultured renal epithelial cells. Biochemical Pharmacology, 1997, 54, 1037-1046.	4.4	11
355	Competitive and non-competitive inhibition of l-3,4-dihydroxyphenylalanine uptake in Opossum kidney cells. European Journal of Pharmacology, 1997, 332, 219-225.	3.5	3
356	Dopamine D2-like receptors in the rat kidney: Effect of denervation. European Journal of Pharmacology, 1997, 334, 233-240.	3.5	9
357	Opossum kidney (OK) cells in culture synthesize and degrade the natriuretic hormone dopamine: A comparison with rat renal tubular cells. International Journal of Biochemistry and Cell Biology, 1997, 29, 681-688.	2.8	22
358	OPOSSUM KIDNEY CELLS TAKE UP L-DOPA THROUGH AN ORGANIC CATION POTENTIAL-DEPENDENT AND PROTON-INDEPENDENT TRANSPORTER. Cell Biology International, 1997, 21, 249-255.	3.0	9
359	Amino acid and metal content ofCrassostrea gigasshell infested byPolydorasp. in the prismatic layer insoluble matrix and blister membrane. Aquatic Living Resources, 1996, 9, 179-186.	1.2	9
360	High sodium intake increases the urinary excretion of L-3,4-dihydroxyphenylalanine but fails to alter the urinary excretion of dopamine and amine metabolites in wistar rats. General Pharmacology, 1996, 27, 1421-1427.	0.7	10

#	Article	IF	Citations
361	A COMPARATIVE STUDY ON THE SYNTHESIS OF THE NATRIURETIC HORMONE DOPAMINE IN OK AND LLC-PK1CELLS. Cell Biology International, 1996, 20, 539-544.	3.0	8
362	Nature and kinetic characteristics of L-DOPA uptake in rat renal proximal tubules. Amino Acids, 1995, 8, 265-270.	2.7	3
363	Studies on the Nature of the Antagonistic Actions of Dopamine and 5-Hydroxytryptamine in Renal Tissues. Hypertension Research, 1995, 18, S47-S51.	2.7	12
364	Ontogeny of the cell outward dopamine transporter in canine renal tissues. Fundamental and Clinical Pharmacology, 1995, 9, 255-262.	1.9	4
365	Endogenous dopamine modulates jejunal sodium absorption during high-salt diet in young but not in adult rats. Gastroenterology, 1994, 107, 675-679.	1.3	52
366	Outflow of dopamine and noradrenaline originating from l-DOPA and in rat renal tissues. General Pharmacology, 1994, 25, 879-885.	0.7	1
367	Isosorbide 5-mononitrate reverses high blood pressure in methyl ester treated rats. General Pharmacology, 1994, 25, 1329-1336.	0.7	1
368	A comparative study on the synthesis of dopamine in the human, dog and rat kidney. Acta Physiologica Scandinavica, 1993, 148, 347-351.	2.2	11
369	Preferential decarboxylation of l-threo-3,4-dihydroxyphenylserine in rat renal tissues. General Pharmacology, 1993, 24, 75-81.	0.7	4
370	Enhanced protein kinase C mediated inhibition of renal dopamine synthesis during high sodium intake. Biochemical Pharmacology, 1993, 45, 1791-1800.	4.4	18
371	Renal tubular dopamine outward transfer during Na+-H+ exchange activation by Î±1- and Î±2-adrenoceptor agonists. British Journal of Pharmacology, 1993, 109, 569-576.	5.4	11
372	Kinetic study of the tubular dopamine outward transporter in the rat and dog kidney. British Journal of Pharmacology, 1993, 109, 577-580.	5.4	11
373	A study on the neuronal and non-neuronal stores of dopamine in rat and rabbit kidney. Pharmacological Research, 1992, 26, 161-171.	7.1	4
374	Actin cytoskeleton, tubular sodium and the renal synthesis of dopamine. Biochemical Pharmacology, 1992, 44, 1883-1886.	4.4	12
375	Deamination of newlyâ€formed dopamine in rat renal tissues. British Journal of Pharmacology, 1991, 102, 778-782.	5.4	28
376	Relaxant effects of Î±â€human atrial natriuretic peptide on venous smooth muscle. Autonomic and Autacoid Pharmacology, 1991, 11, 139-145.	0.6	3
377	Effects of sympathetic denervation on liver fibroblasts: prevention by adenosine. Autonomic and Autacoid Pharmacology, 1990, 10, 181-189.	0.6	14
378	Role of type A and B monoamine oxidase on the formation of 3,4-dihydroxyphenylacetic acid (DOPAC) in tissues from the brain of the rat. Neuropharmacology, 1990, 29, 875-879.	4.1	31

#	Article	IF	Citations
379	Overflow of endogenous dopamine and 3,4-dihydroxyphenylacetic acid from tissues of the rat brain, elicited by electrical stimulation, depolarization by potassium and activation of carrier-mediated release. Neuropharmacology, 1990, 29, 1151-1159.	4.1	17
380	A kinetic study of the rate of formation of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the brain of the rat: Implications for the origin of dopac. Neuropharmacology, 1990, 29, 869-874.	4.1	59
381	Further evidence for a noradrenalineâ€independent storage of dopamine in the dog kidney. Autonomic and Autacoid Pharmacology, 1988, 8, 127-134.	0.6	7
382	Evidence for dopaminergic coâ€transmission in dog mesenteric arterial vessels. British Journal of Pharmacology, 1988, 95, 218-224.	5.4	14
383	Dopamine released from nerve terminals activates prejunctional dopamine receptors in dog mesenteric arterial vessels. British Journal of Pharmacology, 1987, 91, 591-599.	5.4	15
384	A comparison between the pattern of dopamine and noradrenaline release from sympathetic neurones of the dog mesenteric artery. British Journal of Pharmacology, 1987, 90, 91-98.	5.4	42
385	A comparison of the action of the endotheliumâ€derived relaxant factor and the inhibitory factor from the bovine retractor penis on rabbit aortic smooth muscle. British Journal of Pharmacology, 1986, 87, 175-181.	5.4	13
386	Evidence for a non-precursor dopamine pool in noradrenergic neurones of the dog mesenteric artery. Naunyn-Schmiedeberg's Archives of Pharmacology, 1986, 333, 219-223.	3.0	40
387	Fibroblasts and Sympathetic Innervation of Blood Vessels. Journal of Vascular Research, 1985, 22, 278-285.	1.4	7
388	EFFECTS OF CHEMICAL SYMPATHECTOMY ON DOPAMINE AND NORADRENALINE CONTENT OF THE DOG GASTROINTESTINAL TRACT*. Autonomic and Autacoid Pharmacology, 1985, 5, 189-196.	0.6	28